Skip to main content

Table 4 Comparison of clinical, imaging, and laboratory features among different autoantibodies profiles in patients with dermatomyositis

From: Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study

Characteristics

ANA

Anti-ARS

Anti-MDA-5

Anti-Mi-2

Anti-Ro-52

(n = 62)

(n = 13)

(n = 10)

(n = 10)

(n = 26)

Age at diagnosis (years)

47.9 (16.1)

47.2 (11.1)d

45.8 (17.2)

50.5 (12.6)d

49 (13.9)

Female gender

40 (64.5)

9 (69.2)e

4 (40.0)a,e

8 (80.0)e

16 (61.5)

White ethnicity

49 (79.0)

11 (84.6)e

7 (70.0)e

8 (80.0)e

19 (73.1)

Fever/weight loss

56 (90.3)e

12 (92.3)e

10 (100)e

10 (100)e

25 (96.2)e

Gottron’s sign

61 (98.4)e

12 (92.3)e

10 (100)e

10 (100)e

26 (100)e

Heliotrope rash

57 (91.9)a,e

9 (69.2)e

9 (90.0)e

7 (70.0)e

21 (80.8)

“V”-neck sign

51 (82.3)

5 (38.5)b,e

10 (100)e

8 (80.0)e

20 (76.9)e

“Shawl” sign

37 (59.7)

4 (30.8)a,e

8 (80.0)e

8 (80.0)e

14 (53.8)

Raynaud’s phenomenon

42 (67.7)a

7 (53.8)e

7 (70.0)e

7 (70.0)e

19 (73.1)

“Mechanics’ hands”

15 (24.2)

7 (53.8)a,e

4 (40.0)e

0e

11 (42.3)b

Digital ulcers

13 (21.0)

0e

5 (50.0)b,e

2 (20.0)e

4 (15.4)e

Vasculitis

20 (32.3)

1 (7.7)a,e

8 (80.0)b,e

3 (30.0)e

9 (34.6)

Calcinosis

2 (3.2)e

0e

0e

0e

0e

Muscle weakness

19 (30.6)

3 (23.1)e

2 (20.0)e

5 (50.0)e

5 (19.2)

Dysphagia

45 (72.6)

8 (61.5)e

8 (80.0)e

7 (70.0)e

20 (76.9)

Arthritis

21 (33.9)

8 (61.5)e

7 (70.0)a,e

1 (10.0)e

15 (57.7)a

ILD

23 (37.1)

9 (69.2)b,e

4 (40.0)e

0a,e

13 (50.0)

RP-ILD

10 (16.1)e

4 (30.8)e

2 (20.0)e

0e

8 (30.8)e

Maximum CPK (U/L)

1245 (189–3931)d

585 (216–5323)d

158 (91–857)a,d

4783 (3366–8915)b,d

301 (117–2781)d

ANA

8 (61.5)e

8 (80.0)e

9 (90.0)e

18 (69.2)

Anti-ARS

8 (12.9)c,e

0e

0e

8 (30.8)e

Anti-MDA-5

8 (12.9)c,e

0e

0e

7 (26.9)a,e

Anti-Mi-2

9 (14.5)c,e

0e

0e

0a,e

Anti-Ro-52

18 (29.0)c

8 (61.5)a,e

7 (70.0)a,e

0a,e

Severe infections

32 (51.6)

5 (38.5)

5 (50.0)e

5 (50.0)e

12 (46.2)

Neoplasia

12 (19.4)

2 (15.4)e

1 (10.0)e

0e

5 (19.2)

Complete clinical response

31 (50.0)

8 (61.5)

4 (40.0)e

6 (60.0)e

14 (53.8)

Disease remission

22 (35.5)

4 (30.8)e

1 (10.0)e

4 (40.0)e

7 (26.9)

Active disease

9 (14.5)

1 (7.7)e

5 (50.0)a,e

0e

5 (19.2)e

Death

6 (9.7)e

2 (15.4)e

0e

0e

3 (11.5)e

  1. ANA, antinuclear antibody; ARS, anti-tRNA synthetase; CPK, creatine phosphokinase; ILD, interstitial lung disease; RP, rapidly progressive
  2. Data are expressed as a percentage (%) or median (IQR 25–75). To determine differences between patients with and without the specific autoantibody, Student’s t-test was used for continuous variables, unless otherwise stated; for categorical variables, differences were calculated using the chi-squared test, unless otherwise stated
  3. aP < 0.05
  4. bP < 0.01
  5. cData available from 52 patients
  6. dMann–Whitney U test
  7. eFisher’s exact test